Navigation Links
PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
Date:9/13/2012

s: A Phase II Dose and Frequency Finding Study, will be presented during the September 14, 2012 poster session.  For more information, visit http://www.enea2012.org.

ABOUT PROLOR
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins.  PROLOR is currently developing a long-acting version of human growth hormone, which successfully completed a Phase II clinical trial.  It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development.  For more information, visit http://www.prolor-biotech.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of PROLOR's long-acting protein programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoiet
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
2. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
3. Why Texas is #1 in Business: Local BioTech Company Expands
4. RayBiotech, Inc. Achieves Both GMP- and GLP-Compliance and Announces New Dedicated Services Laboratory
5. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
6. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
7. Biomass characterization technology research highlighted in Industrial Biotechnology journal
8. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
9. Global Marine Biotechnology Industry
10. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
11. India Biotechnology in India Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using ... cell therapy treatments for central nervous system diseases, announced ... the NASDAQ Capital Market under the symbol "CUR." The ... NYSE MKT until the market close on July 10, ... to commence on July 13, 2015. ...
(Date:6/29/2015)... Louis, MO (PRWEB) , ... June 29, 2015 , ... ... 15 – July 16 and for the fourth year in a row, will bring ... what changes are taking place at the intersection of data and technology. The event ...
(Date:6/29/2015)... 29, 2015   For the seventh year running, Across ... their overall digital maturity called the Multichannel Maturometer ... are not maturing fast enough. While it,s true that ... ways overall and customers are increasingly "digital natives", pharma ... customer engagement.  ...
(Date:6/26/2015)... Mass. , June 26, 2015  SeraCare ... vitro diagnostics manufacturers, today announced that it has ... with the National Cancer Institute (NCI), part of ... materials and positive controls for cancer assays.  The ... mix and accurately quantitate control DNA biosynthetics spiked ...
Breaking Biology Technology:Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3
... Imago MADISON, Wis. Mass storage vendor ... Imago Scientific Instruments to meet the manufacturing challenges ... that Seagate has adopted Imago's LEAP Microscope to provide ... magnetic heads and media. , ,According to the company, ...
... RFID tag MADISON, Wis. A new RFID ... advance showing September 29 to attendees of the its ... is holding its seventh annual E-Business Best Practices ... , ,RFID, which involves tagging products or shipments with ...
... BROOKFIELD, Wis. Fiserv Imagesoft , a ... on Thursday that it has completed enhancement of its ... toward improving the security of image replacement documents (IRDs), ... an original check. , ,The new features of ExchangeGuard ...
Cached Biology Technology:E-business conference to give sneak peek into university RFID laboratory 2
(Date:6/16/2015)... Sweden , June 16, 2015 ... all touch fingerprint sensors in the company,s portfolio from one ... Deliveries are planned to mainly take place during the third ... in Asia . Jörgen Lantto, ... evidence of    the   growing interest from smartphone OEMs ...
(Date:6/15/2015)... According to a new market research report ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) ... Natural Language Processing Market is expected to grow to ... forecast period 2015-2020. Browse 65 market ...   through 155 P ages and in-depth TOC ...
(Date:6/15/2015)... 15, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces that its leading payment security ... at Digital Experience! @ NYC June 18th. Digital ... latest innovation in technology to over 300 of the top ... the Metropolitan Pavilion in New York City ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... 2011 GNS Healthcare, Inc. (GNS) is ... lung cancer research with a supercomputing platform that can ... assembled from imaging, genetics, pathology, and other areas. The ... a given treatment. GNS will analyze NCI ...
... TORONTO, Ont., July 12, 2001--Eating nuts every day could ... according to new research from St. Michael,s Hospital and ... online by the journal Diabetes Care , a ... of Toronto Department of Nutritional Sciences; St. Michael,s Hospital ...
... 07/07/11, Clearwater Beach, FL. Research to be presented at ... of Ingestive Behavior (SSIB), the foremost society for research into ... a naturally occurring gut hormone, increases our willingness to pay ... non-food items. Have you ever wondered about why you ...
Cached Biology News:GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients 2GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients 3A 'nutty' solution to type 2 diabetes management 2